Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Non-small cell lung cancer" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-14 z 14
    Tytuł:
    Reference genes for gene expression studies on non-small cell lung cancer
    Autorzy:
    Gresner, Peter
    Gromadzinska, Jolanta
    Wasowicz, Wojciech
    Powiązania:
    https://bibliotekanauki.pl/articles/1040589.pdf
    Data publikacji:
    2009
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    non-small cell lung cancer
    reference genes
    data normalization
    real-time PCR
    gene expression
    Opis:
    Study Objective: The aim of this study was to test a panel of 6 reference genes in order to identify and validate the most suitable reference genes for expression studies in paired healthy and non-small cell lung cancer tissues. Method: Quantitative real-time PCR followed by the NormFinder- and geNorm-based analysis was employed. The study involved 21 non-small cell lung cancer patients. Results: The analysis of experimental data revealed HPRT1 as the most stable gene followed by RPLP0 and ESD. In contrast, GAPDH was found to be the least stable gene. HPRT1 together with ESD was revealed as the pair of genes introducing the least systematic error into data normalization. Validation by bootstrap random sampling technique and by normalizing exemplary gene expression data confirmed the results. Conclusion: Although HPRT1 and ESD may by recommended for data normalization in gene expression studies on non-small cell lung cancer, the suitability of selected reference genes must be unconditionally validated prior to each study.
    Źródło:
    Acta Biochimica Polonica; 2009, 56, 2; 307-316
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Long non-coding RNA and Notch regulation in non-small cell lung cancer
    Autorzy:
    Pancewicz, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1918915.pdf
    Data publikacji:
    2020-06-10
    Wydawca:
    Uniwersytet Medyczny w Białymstoku
    Tematy:
    Notch
    non-small cell lung cancer
    lncRNAs
    Opis:
    Non-small cell lung cancer is one of the most commonly diagnosed cancer with a very high mortality rate. Trying to understand the mechanisms underlying the progression of this type of cancer, it is necessary to evaluate the changes occurring at molecular level in cancer cells. Besides the widely studied signaling pathways and genes which are dysregulated in NSCLC, there is a large group of non-coding RNAs involved in cancer pathogenesis. Those RNAs are tissue specific heterogeneous class of RNAs that play many functions in physiological condition in cells, nevertheless current data has shown that lncRNAs are also functional in different types of cancer. Moreover, it has been suggest that lncRNAs are involved in cancer progression by controlling key signaling pathways involved in diverse types of tumors. Notch signaling is one of those pathways, very often deregulated in NSCLC. Therefore in this review I summarized recent outcomes according the importance of lncRNAs in regulation of Notch pathway in the pathogenesis of NSCLC.
    Źródło:
    Progress in Health Sciences; 2020, 10(1); 108-122
    2083-1617
    Pojawia się w:
    Progress in Health Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Differential Notch1 and Notch2 expression in non-small cell lung cancer
    Autorzy:
    Pancewicz, J.
    Bernatowicz, P.L.
    Powiązania:
    https://bibliotekanauki.pl/articles/1918837.pdf
    Data publikacji:
    2019
    Wydawca:
    Uniwersytet Medyczny w Białymstoku
    Tematy:
    NOTCH1
    NOTCH2
    NSCLC
    HBEpC
    Opis:
    Introduction: NOTCH signaling can be deregulated in non-small cell lung cancer and can have oncogenic or tumor suppressive functions. NOTCH1 is regulated equally with NOTCH2, and the stability of the expression of those Notch receptors could determine the biological functions of lung cancer cells. Purpose: To estimate expression level of NOTCH2 receptor in diverse NSCLC cell lines. Furthermore, we compared the mRNA level of NOTCH2 expression to the level of NOTCH1 expression. Materials and methods: We have evaluated the mRNA manifestation of NOTCH1 and NOTCH2 genes by using quantitative real time method (RT-PCR). Moreover, we associated the results from NSCLC cells with results achieved in non-cancerous human bronchial epithelial cells (HBEpC). Results: The expression level of NOTCH1 and NOTCH2 was downregulated in NSCLC cell lines, when related to HBEpC. Nevertheless, the decrease in NOTCH1 expression was significant, whereas NOTCH2 was not much different from the expression in control cells. Conclusions: We conclude that NOTCH1 and NOTCH2 most likely have different biological function in NSCLC. They are active in NSCLC cell lines; nonetheless both are downregulated in lung cancer cells used in this study. Moreover, NOTCH2 expression is comparatively higher than NOTCH1 expression.
    Źródło:
    Progress in Health Sciences; 2019, 1; 8-12
    2083-1617
    Pojawia się w:
    Progress in Health Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Identification of serum proteome components associated with progression of non-small cell lung cancer
    Autorzy:
    Pietrowska, Monika
    Jelonek, Karol
    Michalak, Malwina
    Roś, Małgorzata
    Rodziewicz, Paweł
    Chmielewska, Klaudia
    Polański, Krzysztof
    Polańska, Joanna
    Gdowicz-Kłosok, Agnieszka
    Giglok, Monika
    Suwiński, Rafał
    Tarnawski, Rafał
    Dziadziuszko, Rafał
    Rzyman, Witold
    Widłak, Piotr
    Powiązania:
    https://bibliotekanauki.pl/articles/1039297.pdf
    Data publikacji:
    2014
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    cancer staging
    early detection
    lung cancer
    proteomics
    serum biomarkers
    Opis:
    The aim of the present study was to perform comparative analysis of serum from patients with different stages of non-small cell lung cancer (NSCLC) using the three complementary proteomic approaches to identify proteome components associated with the progression of cancer. Serum samples were collected before any treatment from 200 patients with NSCLC, including 103 early stage, 64 locally advanced and 33 metastatic cancer samples, and from 200 donors without malignancy. The low-molecular-weight fraction of serum proteome was MALDI-profiled in all samples. Serum proteins were characterized using 2D-PAGE and LC-MS/MS approaches in a representative group of 30 donors. Several significant differences were detected between serum samples collected from patients with early stage cancer and patients with locally advanced cancer, as well as between patients with metastatic cancer and patients with local disease. Of note, serum components discriminating samples from early stage cancer and healthy persons were also detected. In general, about 70 differentiating serum proteins were identified, including inflammatory and acute phase proteins already reported to be associated with the progression of lung cancer (serum amyloid A or haptoglobin). Several differentiating proteins, including apolipoprotein H or apolipoprotein A1, were not previously associated with NSCLC. No significant differences in patterns of serum proteome components were detected between patients with adenocarcinoma and squamous cell carcinoma. In conclusion, we identified the biomarker candidates with potential importance for molecular proteomic staging of NSCLC. Additionally, several serum proteome components revealed their potential applicability in early detection of the lung cancer.
    Źródło:
    Acta Biochimica Polonica; 2014, 61, 2; 325-331
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    A brief dive into the phenomenon of cisplatin resistance in non-small-cell lung cancer
    Autorzy:
    Sobczak, Maciej
    Powiązania:
    https://bibliotekanauki.pl/articles/1830652.pdf
    Data publikacji:
    2021-09-29
    Wydawca:
    Uniwersytet Łódzki. Wydawnictwo Uniwersytetu Łódzkiego
    Tematy:
    non-small-cell lung cancer
    cisplatin
    cisplatin resistance
    Opis:
    Lung cancer is one of the most lethal types of cancer due to a lack of proper treatment. The rare presence of molecular therapy targets forces the use of platinum-based drugs. Cisplatin, approved by the USA as an anticancer therapy in the 1970s, is still one of the most prominent therapies against lung cancer. Unfortunately, the biggest limitation of cisplatin-based therapy is the development of cisplatin resistance. Cancer cells overcome the vast DNA damage caused by the drug in a variety of ways such as detoxication and extracellular transport of the drug, enhanced repair mechanisms, omitting apoptosis and epigenetic alterations. Chemotherapy resistance is an issue that so far cannot be dealt with. Nevertheless, better understanding of the molecular pathways behind cisplatin resistance brings hope for better therapy outcomes in lung cancer patients.
    Źródło:
    Acta Universitatis Lodziensis. Folia Biologica et Oecologica; 2021, 17; 37-41
    1730-2366
    2083-8484
    Pojawia się w:
    Acta Universitatis Lodziensis. Folia Biologica et Oecologica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Clinical and prognostic value of hTERT mRNA expression in patients with non-small-cell lung cancer
    Autorzy:
    Zalewska-Ziob, Marzena
    Dobija-Kubica, Katarzyna
    Biernacki, Krzysztof
    Adamek, Brygida
    Kasperczyk, Janusz
    Bruliński, Krzysztof
    Ostrowska, Zofia
    Powiązania:
    https://bibliotekanauki.pl/articles/1038550.pdf
    Data publikacji:
    2017
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    non-small-cell lung cancer
    telomerase
    hTERT expression
    survival rate
    prognosis
    Opis:
    Telomerase, undetectable in normal somatic cells, plays a critical role in carcinogenesis of the majority of human tumors including lung carcinoma. The aim of our study was to determine human telomerase reverse transcriptase (hTERT) mRNA expression in patients with non-small cell lung cancer (NSCLC) in order to estimate its usefulness as diagnostic and/or prognostic factor. hTERT expression was analyzed in a group of 12 females and 28 males with NSCLC using Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR method) in cancerous and non-cancerous lung tissues. Results were analyzed according to clinical data and one-, two-, and five-year survival rates. hTERT expression in the cancerous tissue was significantly higher than in the lung parenchyma free from neoplasm infiltration (p<0.05). There was no significant association between hTERT expression in the tumor tissue and age, gender, grading or clinical stage. A significant difference in hTERT expression between two types of histopathological patterns (adenocarcinoma and squamous cell carcinoma) was detected (p=0.01). No association between hTERT expression in NSCLC specimens and survival rates was found. hTERT mRNA detection by QRT-PCR in tumor and corresponding cancer-free tissues can be used as a diagnostic marker in patients with NSCLC, but seems not to be a prognostic factor.
    Źródło:
    Acta Biochimica Polonica; 2017, 64, 4; 641-646
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The current state of knowledge on small cell and non-small cell lung cancer and the position of durvalumab immunotherapy in lung cancer treatment
    Autorzy:
    Poboży, Kamil
    Domańska, Julia
    Domański, Paweł
    Powiązania:
    https://bibliotekanauki.pl/articles/3200762.pdf
    Data publikacji:
    2023-01-24
    Wydawca:
    Medical Education
    Tematy:
    PD-L1
    immunotherapy
    durvalumab
    neoplasm
    oncology
    SCLC
    NSCLC
    Opis:
    Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer-related deaths in the world. These statistics make lung cancer one of the most important targets for modern medicine. The identification of multiple risk factors, including tobacco smoking, has been fundamental in understanding the disease. Late-stage detection is a significant contributor to the high mortality rate of lung cancer. Nonetheless, the role of screening is still debatable. The selection of therapy is primarily based on distinguishing between small-cell and non-small cell lung cancer. Despite the major differences in treatment, in both types in specific situations the treatment involves durvalumab – a monoclonal antibody targeting the programmed cell death ligand 1 molecule, which is often present on tumor cells and protects them against the patient’s immune system. The efficacy of durvalumab has been demonstrated in two randomized, multicenter clinical trials. The aim of this study is to summarize the current state of knowledge about lung cancer and durvalumab. Despite the current 5-year survival rate of 19% in lung cancer, the development of immunotherapeutics such as durvalumab may be the key to improving the unfavorable prognosis of lung cancer in the future.
    Źródło:
    OncoReview; 2022, 12, 4; 75-82
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
    Autorzy:
    Kardas, Joanna
    Buraczewska, Agnieszka
    Chrom, Paweł
    Waśko-Grabowska, Anna
    Młot, Beata
    Szczylik, Cezary
    Powiązania:
    https://bibliotekanauki.pl/articles/773534.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    endothelial growth factor receptor
    non-small cell lung cancer
    tyrosine kinase inhibitor
    Opis:
    Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objective: The evaluation of the efficacy and toxicity of TKI drugs in NSCLC patients treated in single centre. Material and methods: NSCLC patients treated with TKI (gefitinib, erlotynib, afatinib) between 2012– 2016 were retrospectively analysed. We evaluated: overall response rate (ORR) which is the sum of complete responses (CR) and partial remissions (PR), progression free survival (PFS), overall survival (OS) and adverse events (AE) according to CTCAE (Common Terminology Criteria for Adverse Events) scale. Results: The study group were 16 patients ORR was 50% (CR: 1, PR: 7). Median PFS and OS was 8,7 and 22,9 months respectively. Adverse events observed mainly in stage 1 and 2 were related to hyponatraemia, hyperbilirubinemia, skin toxicity and mucositis. There was one death reported due to infectious complications. Conclusion: The efficacy and toxicity of TKI in study group were found to be similar to those described in the literature.
    Źródło:
    OncoReview; 2017, 7, 2; 92-97
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Human bronchial epithelial cells as a good control for evaluation potential therapeutic Notch signaling in non-small cell lung cancer
    Autorzy:
    Pancewicz, J.
    Bernatowicz, P.L.
    Golec, P.
    Powiązania:
    https://bibliotekanauki.pl/articles/1918632.pdf
    Data publikacji:
    2018-06-18
    Wydawca:
    Uniwersytet Medyczny w Białymstoku
    Tematy:
    Notch
    NSCLC
    HBEpC
    Opis:
    Purpose: Notch signaling is often deregulated in non-small cell lung cancer (NSCLC), but little is known about the initial endogenous mRNA status of Notch ligands and receptors. Therefore, the aim of this study was to evaluate expression level of NOTCH1 receptor and Notch ligands, such as delta like ligands (DLL1, DLL3, DLL4), and jagged ligands (JAG1, JAG2), as well as target gene-hes family bHLH transcription factor 1 (HES1) in diverse NSCLC cell lines. Materials and Methods: We have investigated the mRNA expression of chosen genes by using quantitative real time method (RT-PCR). We compared the results from NSCLC cells with results obtained in non-cancerous human bronchial epithelial cells (HBEpC). We also measured NOTCH1 expression in A549 cells, before and after treatment with γ-secretase inhibitor (GSI). Results: The expression level of NOTCH1, HES1, JAG1 and JAG2 was downregulated when compared to HBEpC. The expression of Notch ligand DLL1 was lower in all cancer cell lines, but mRNA level of DLL3 was elevated in H1299 and A549 cells when related to HBEpC. The mRNA level of DLL4 was higher in H520 and in A549 cell lines. Moreover, the mRNA level of NOTCH1 dropped down after GSI treatment, in addition A549 cells proliferated slower after drug implementation. Conclusions: We conclude that non-cancerous HBEpC cells could serve as a good control for Notch mRNAs expression analysis in NSCLC. Moreover, GSI-treated cells could inhibit proliferation through suppressing NOTCH1 in A549 cells. Keywords: Notch, NSCLC, HBEpC
    Źródło:
    Progress in Health Sciences; 2018, 8(1); 7-13
    2083-1617
    Pojawia się w:
    Progress in Health Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
    Autorzy:
    Bargiel, J.B.
    Cabaj, J.
    Chmielewska, I.
    Milanowski, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/2098542.pdf
    Data publikacji:
    2021
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    non-small cell lung cancer
    crizotinib
    therapy
    gene rearrangement
    tyrosine kinase inhibitor
    patient
    Opis:
    Introduction. Currently, nearly 23,000 cases of lung cancer are diagnosed in Poland annually, of which 5% are cases with rearrangements in the ALK gene. In recent years, tremendous progress has been made in understanding the genetic makeup of this type of cancer, which has enabled the use of new therapies, in particular, molecularly targeted drugs. Crizotinib is the first oral small molecule inhibitor of ALK, MET and ROS1 receptor tyrosine Kinases approved by the European Medicines Agency(EMA). Case report. The paper presents the case of a 62-year-old patient diagnosed with non-small cell lung cancer with rearrangement in the ALK gene in stage IV of the disease. The patient was qualified for treatment with crizotinib under the B6 drug programme. Treatment started in May 2019. During treatment, assessment was made at 3 control points, where the first and second showed a partial response according to the RECIST 1.1 scale; in the next assessment, the response was maintained in the form of disease stabilization.
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2021, 15, 3; 151-154
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Differentiation by random amplified polymorphic DNA-polymerase chain reaction (RAPD-PCR) of Candida albicans isolated from upper respiratory tract in patients with non-small cell lung cancer
    Autorzy:
    Biernasiuk, Anna
    Korona-Głowniak, Izabela
    Grzegorczyk, Agnieszka
    Malm, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/1039202.pdf
    Data publikacji:
    2014
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    RAPD-PCR
    Candida albicans
    upper respiratory tract
    genetic diversity
    Opis:
    Cancer patients are predisposed to fungal infections caused by Candida albicans, especially to oral or respiratory tract candidiasis. The aim of this study was to estimate genetic diversity by RAPD-PCR (random amplified polymorphic DNA-polymerase chain reaction) of C. albicans isolated from upper respiratory tract of 100 patients with non-small cell lung cancer. Among 52 strains, 34 genotypes were defined. 10 clusters comprising 28 (53.85%) isolates with similarity coefficient ≥ 80% were formed. The remaining 24 (46.15%) isolates represented individual genotypes. The RAPD-PCR technique revealed genomic variability within C. albicans isolated from upper respiratory tract of the cancer patients.
    Źródło:
    Acta Biochimica Polonica; 2014, 61, 4; 727-729
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Life Expectancy in Patients With Stage III A Non-small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoradiotherapy (NCRT), Neoadjuvant Chemotherapy (NCT), Neoadjuvant Chemotherapy + Adjuvant Radiation Therapy (NCT + Adjuvant RT)
    Przewidywana długość życia u pacjentów z niedrobnokomórkowym rakiem płuca w stadium III A (NSCLC) poddanych neoadjuwantowej chemioradioterapii (NCRT), neoadjuwantowej chemioterapii (NCT), neoadjuwantowej chemioterapii + adjuwantowej radioterapii (NCT + adjuwantowa RT)
    Autorzy:
    Maliarchuk, Katerina
    Ganul, Andrey
    Borisyuk, Bogdan
    Bororov, Leonid
    Shevchenko, Anatoly
    Sovenko, Vladimir
    Kutsenko, Lubov
    Powiązania:
    https://bibliotekanauki.pl/articles/2159225.pdf
    Data publikacji:
    2022-12-30
    Wydawca:
    Akademia Bialska Nauk Stosowanych im. Jana Pawła II w Białej Podlaskiej
    Tematy:
    neoadjuvant therapy
    pneumonectomy
    lobectomy
    non-small cell lung cancer
    overall survival
    terapia neoadjuwantowa
    pneumonektomia
    lobektomia
    niedrobnokomórkowy rak płuca
    choroby
    przeżycie całkowite
    Opis:
    Background. This work is а comparative study of survival in patients with stage III A non-small cell lung cancer (NSCLC) treated with neoadjuvant chemoradiotherapy (NCRT), neoadjuvant chemotherapy (NCT) and neoadjuvant chemotherapy and adjuvant radiation therapy (NCT + adjuvant RT). Material and methods. Three groups of 65 people were selected. The first group received NCT, the second group – NCT, and the third group – NCT + adjuvant radiation therapy. The NCRT group received radiation therapy of 30 Gy. Survival was assessed using the Kaplan and Mayer scale and according to the log rank criteria. Results. The statistical criterion for NCRT in relation to NCT was -3.51279, r=0.00044. The statistical criterion for NCRT in relation to NCT + adjuvant RT was -2.88568, r=0.00391. Less reliable dependence was observed between NCT and NCT + adjuvant RT (the statistical criterion =1.809508, p=0.070307). Conclusions. Performing NCT, NCRT or NCT + RT and the status of complete morphological response (CMR) during the revision of histological material, it is possible to predict survival for a period of up to 36 months. NCRT is the optimal method of treatment.
    Wprowadzenie. Niniejsza praca stanowi badanie porównawcze przeżycia u pacjentów z niedrobnokomórkowym rakiem płuca w stadium III A (NSCLC) w leczeniu neoadjuwantową chemioradioterapią (NCRT), neoadjuwantową chemioterapią (NCT) oraz neoadjuwantową chemioterapią i adjuwantową radioterapią (NCT + adjuwantowa RT). Materiał i metody. Wyłoniono 3 grupy po 65 osób. Pierwsza grupa otrzymała NCT, druga grupa – NCRT, a trzecia grupa – NCT + radioterapię adjuwantową. Grupa NCRT otrzymała radioterapię w dawce 30 Gy. Przeżycie oceniano za pomocą skali Kaplana i Mayera oraz według kryteriów log rank. Wyniki. Kryterium statystyczne NCRT w stosunku do NCT wyniosło -3,51279, r=0,00044. Kryterium statystyczne NCRT w stosunku do NCT + adjuwantowej RT wyniosło -2,88568, r=0,00391. Mniej wiarygodna zależność została zaobserwowana między NCT a NCT + adjuwantowa RT (kryterium statystyczne = 1,809508, p=0,070307). Wnioski. Wykonując NCT, NCRT lub NCT + RT oraz status całkowitej odpowiedzi morfologicznej (CMR) podczas rewizji materiału histolog
    Źródło:
    Health Problems of Civilization; 2022, 16, 4; 302-311
    2353-6942
    2354-0265
    Pojawia się w:
    Health Problems of Civilization
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Association between polymorphisms in CHRNA3 and PHACTR2 gene and environment and NSCLC risk in Chinese population
    Autorzy:
    Lou, Guangyuan
    Zhang, Yongjun
    Bao, Wenlong
    Deng, Dehou
    Powiązania:
    https://bibliotekanauki.pl/articles/1039210.pdf
    Data publikacji:
    2014
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    Non-small cell lung cancer
    phosphatase and actin regulator 2 (PHACTR2)
    cholinergic receptor
    nicotinic
    alpha 3 (CHRNA3)
    single-nucleotide polymorphism
    Opis:
    Aims. This study aimed to investigate CHRNA3 (rs8040868) and PHACTR2 (rs9390123) single-nucleotide polymorphisms (SNPs) for association with non-small-cell lung cancer (NSCLC) risk in a Chinese population, and whether the environment affects the genetic polymorphisms. Methods. This case and control study included 500 NSCLC patients and 500 age-matched healthy controls. CHRNA3 (rs8040868) and PHACTR2 (rs9390123) SNPs were genotyped and associated for NSCLC risk by computing the odds ratio and 95% confidence interval from multivariate unconditional logistic regression analyses with adjustment of age. Results. The minor allele frequency (MAF) of CHRNA3 (rs8040868) and PHACTR2 (rs9390123) was 0.350 (C) and 0.397 (C), respectively. The frequencies of genotype and allele in CHRNA3 (rs8040868) and PHACTR2 (rs9390123) were not significantly different between the cases and controls, or between either of the subgroups. Conclusion. Although rs8040868 and rs9390123 SNPs are not associated with NSCLC risk in Chinese population, the results strongly suggest that geographical agents interact with human genetic polymorphism independent of ethnic background.
    Źródło:
    Acta Biochimica Polonica; 2014, 61, 4; 765-768
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    First report of the oncolytic effect of EHV-1 on the non-small lung cancer – in vitro studies
    Autorzy:
    Chodkowski, M.
    Słońska, A.
    Bartak, M.
    Bańbura, M.W.
    Cymerys, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/2087133.pdf
    Data publikacji:
    2021
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    EHV-1
    adenocarcinoma cell line
    oncolytic virus
    Źródło:
    Polish Journal of Veterinary Sciences; 2021, 24, 4; 607-610
    1505-1773
    Pojawia się w:
    Polish Journal of Veterinary Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-14 z 14

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies